

Please type a plus sign (+) inside this box → ☒

PTO/SB05 (12/97)  
Approved for use through 08/30/00. OMB 0651-0032  
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 506.35379CC2 Total Pages

First Named Inventor or Application Identifier

HORI, et al.

Express Mail Label No.

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ Fee: \$1346.00

Please charge any shortages in the fees or credit any overpayments thereof to the deposit account of Antonelli, Terry, Stout & Kraus, Deposit Account No. 01-2135.

6. ☐ Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

- a. ☐ Computer Readable Copy  
b. ☐ Paper Copy (identical to computer copy)  
c. ☐ Statement verifying identity of above copies

2. ☒ Specification [Total Pages 27]

3. ☐ Drawing(s) (35 USC 113) [Total Sheets]

4. Oath or Declaration [Total Pages 2]

- a. ☐ Newly executed (original or copy)  
b. ☒ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 6 below]

i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

5. ☒ Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

## ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))  
9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney  
10. ☐ English Translation Document (if applicable)  
11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations  
12. ☐ Preliminary Amendment  
13. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  
14. ☐ Small Entity ☐ Statement filed in prior application, Statement(s) ☐ Status still proper and desired  
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)  
16. ☒ Other: Preliminary Remarks and Letter

17. If CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09, 106, 004

## 18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

020457

(Insert Customer No. or Attach bar code label here)

## 11. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	William I. Solomon	
SIGNATURE	<i>William I. Solomon</i>	
DATE	April 6, 2000	REG. NO. 28,565

ANTONELLI, TERRY, STOUT & KRAUS, LLP

SUITE 1800  
1300 NORTH SEVENTEENTH STREET  
ARLINGTON, VIRGINIA 22209

TELEPHONE  
(703) 312-6600  
FACSIMILE  
(703) 312-6666  
E-MAIL  
email@antonelli.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: HORI, et al.  
Filed: April 6, 2000  
For: LIPID METABOLISM IMPROVING AGENT

PRELIMINARY REMARKS

Assistant Commissioner for Patents  
Washington, D.C. 20231

April 6, 2000

Sir:

Prior to examination of the above-identified application, please note that applicants do not necessarily wish to elect claims previously elected in the prior application Serial No. 08/836,546. If the Examiner intends to maintain a restriction requirement as in the prior application, the Examiner is respectfully requested to issue a written restriction requirement in the present application and permit applicants to make a new election in the present application.

Respectfully submitted,

ANTONELLI, TERRY, STOUT & KRAUS, LLP



William I. Solomon  
Registration No. 28,565

WIS/slk  
(703) 312-6660

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: HORI, et al.  
Filed: April 6, 2000  
For: LIPID METABOLISM IMPROVING AGENT

LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

April 6, 2000

Sir:

Under the provisions of 35 U.S.C. § 119 and 37 CFR 1.55,  
the applicants hereby claim the right of priority based on:  
Japanese Application No. 228928/95, filed September 6,  
1995.

Receipt of the certified copy of said Japanese  
Application has been acknowledged in the Notification of  
Acceptance of Application Under 35 U.S.C. 371 and 37 CFR 1.494  
or 1.495 mailed June 25, 1997 in connection with the above-  
identified application.

Respectfully submitted,

ANTONELLI, TERRY, STOUT & KRAUS, LLP



William I. Solomon  
Registration No. 28,565

1300 North Seventeenth Street  
Suite 1800  
Arlington, VA 22209  
Tel.: 703-312-6600  
Fax.: 703-312-6666

WIS/slk

[illegible]

## LIPID METABOLISM IMPROVING AGENT

### Cross-Reference to Related Application

This application is a Continuation application of application Serial No. 09/106,004, filed June 29, 1998, which is a Continuation application of application Serial No. 08/836,546, filed May 6, 1997, the contents of which are incorporated herein by reference in their entirety.

### 5 Background Art

The term lipid metabolism refers to the in vivo process of catabolism (decomposition) and anabolism (accumulation) of lipids, which are mainly triglycerides derived from food, and is intended to include, in the broad  
10 sense, reactions for transforming lipids into energy, biosynthesis of fatty acids, biosynthesis of acylglycerol, phospholipid metabolism, and cholesterol metabolism [Akira Misaki, *Biochemistry for Nutrition*, Asakura Shoten (1993), p. 123-134].

15 In recent years, mortality from adult diseases, particularly cardiovascular disorders, is rapidly rising, and a correlation between occurrence of such disorders and cholesterol concentration in blood has been pointed out. Some attempts have so far been made to lower the  
20 cholesterol concentration in blood by the use of specific food components. For example, the following proteins are known as proteins which lower the cholesterol concentration in blood: whey protein [*Agric. Biol. Chem.*, 55, 813 (1991)]; soybean protein [*Atherosclerosis*, 72, 115 (1988)];  
25 milk serum protein (Japanese Published Unexamined Patent Application No. 176713/93); and soybean protein hydrolyzate [*J. Nutr.*, 120, 977 (1990)].

It is also known that egg yolk phospholipid lowers the cholesterol concentration in blood [*Agric. Biol. Chem.*, 53,  
30 2469 (1989)].

An attempt has been made to lower the cholesterol concentration in blood by the use of a combination of lactalbumin, collagen, soybean protein, or wheat gluten,

and soybean lecithin (0, 2.5 and 5%) [Nutr. Rep. Int., 28, 621 (1983)].

- Also known is a method for lowering the cholesterol concentration in blood by the use of a textured soybean protein containing 6% of soybean lecithin [Ann. Nutr. Metab., 29, 348 (1985)].

#### Disclosure of the Invention

- The present invention relates to a protein/  
10 phospholipid or protein hydrolyzate/phospholipid complex containing 10 wt% or more of bound phospholipid, a lipid metabolism improving agent comprising the complex, and a functional food comprising the complex.

- The proteins for use in the present invention may be  
15 derived from animals, plants or microorganisms. Suitable examples are wheat protein, soybean protein, corn protein and milk protein, among which wheat protein and soybean protein are preferred. As the wheat protein, wheat gluten is usually used. Wheat gluten, soybean protein, etc. of  
20 commercial origin are readily available.

Examples of the phospholipids are phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, sphingomyelin, phosphatidic acid, and lecithin, which is a mixture of the above members.

- 25 Lecithin derived from animals, plants or microorganisms may be used. Suitable examples are brain lecithin, liver lecithin, egg yolk lecithin, soybean lecithin and yeast lecithin, among which soybean lecithin and egg yolk lecithin are preferred.

- 30 Lecithin may be used as such, but enzyme-modified lecithin obtained by treating lecithin with an enzyme such as phospholipase is preferably used. Lecithin and enzyme-modified lecithin of commercial origin are readily available.

- 35 The term bound phospholipid as used herein refers to a phospholipid which remains bound to a protein after being

treated with a nonpolar organic solvent such as petroleum ether.

The amount of bound phospholipid is calculated as follows. The amount of total phospholipid contained in a protein hydrolyzate/phospholipid complex is determined. Then, the complex is treated with a nonpolar organic solvent such as petroleum ether, and the amount of phospholipid extracted into the solvent (hereinafter referred to as free phospholipid) is determined. The amount of bound phospholipid is calculated as the difference between the amount of total phospholipid and that of free phospholipid.

The bound phospholipid content of a complex is calculated as the percentage of bound phospholipid in the complex (wt%).

The complex of the present invention contains 10% or more, preferably 10-50% of bound phospholipid. Particularly preferred is the complex containing 20-50% of bound phospholipid.

As the protein/phospholipid complex, commercially available ones can be used. The protein/phospholipid complex can also be prepared by mixing 100 parts by weight of a protein and 10-100 parts by weight of a phospholipid using a stirring mixer, preferably in the presence of water. By mixing a protein and a phospholipid at a ratio of 100:20-50 by weight, preferably 100:30-40, a desirable complex can be obtained wherein the bound phospholipid content is high and the ratio of bound phospholipid to total phospholipid is high. In an exemplary preparation process, a solution prepared by dispersing a phospholipid in water is added to a protein, followed by mixing at room temperature by using a high power mixer (50-200 r.p.m.) or a homogenizer (5,000-15,000 r.p.m.).

The protein hydrolyzate/phospholipid complex can be prepared by mixing a protein hydrolyzate and a phospholipid, or by hydrolyzing in an aqueous medium the

protein moiety of a complex prepared by mixing a protein and a phospholipid.

As the protein hydrolyzate, hydrolysed products of proteins in an aqueous medium using a proteolytic enzyme or an acid can be used. Preferred are hydrolyzates slightly soluble in water having a molecular weight of 5,000-30,000, particularly, those having a molecular weight of 10,000-20,000.

A typical example of the method for preparing such slightly water-soluble substances is given below. A protein is dispersed in water, and hydrochloric acid or sodium hydroxide is added to the solution to bring it to the optimum pH range for the proteolytic enzyme to be employed. The proteolytic enzyme is added to the solution in an amount of 0.5-2% based on the substrate protein, followed by reaction at the optimum pH and the optimum temperature for the enzyme for 20-30 hours. The enzyme reaction is terminated by heating at 85-95°C for about one hour. After being neutralized with sodium hydroxide or hydrochloric acid, the reaction mixture is centrifuged to obtain the slightly water-soluble substance.

As the aqueous medium, water, buffers, alcohols, esters, ketones, amides, etc. can be used. Water is preferably used.

As the proteolytic enzyme, pepsin, trypsin, pancreatin, papain, etc. can be used.

The protein hydrolyzate/phospholipid complex can be prepared by mixing 100 parts by weight of a protein hydrolyzate and 10-100 parts by weight of a phospholipid using a stirring mixer, preferably in the presence of water. By mixing a protein and a phospholipid at a ratio of 100:20-50 by weight, preferably 100:30-40, a desirable complex can be obtained wherein the bound phospholipid content is high and the ratio of bound phospholipid to total phospholipid is high. In an exemplary preparation process, a solution prepared by dispersing a phospholipid



in water is added to a protein hydrolyzate, followed by mixing at room temperature by using a high power mixer (50-200 r.p.m.) or a homogenizer (5,000-15,000 r.p.m.).

The protein hydrolyzate/phospholipid complex can also be prepared by the same method as in the preparation of a protein hydrolyzate except that a protein/phospholipid complex is used instead of a protein hydrolyzate. By this method, the protein moiety of the complex is hydrolyzed to give the desired complex as a slightly water-soluble substance having a molecular weight of 5,000-30,000, preferably, 10,000-20,000. The hydrolysis of the protein moiety of the complex is preferably carried out by the treatment with a proteolytic enzyme in an aqueous medium.

As the method for the preparation of the protein hydrolyzate/phospholipid complex, the hydrolysis of the protein moiety of a protein/phospholipid complex in an aqueous medium is preferable to the mixing of a protein hydrolyzate and a phospholipid, because the former gives a higher protein recovery.

The complex of the present invention may be utilized without being isolated from the reaction mixture, or after isolation and purification from the reaction mixture. The product obtained by drying the reaction mixture or the complex by freeze-drying or spray-drying and pulverizing the dried product can also be utilized.

The protein hydrolyzate/phospholipid complex is superior to the protein hydrolyzate/phospholipid complex in lipid metabolism improving effect.

The lipid metabolism improving agent of the present invention may be in any of the dose forms such as tablets, powders, fine granules, granules, capsules, syrups, enteric coated tablets, troches, and liquid preparations for oral administration.

The administration route for the lipid metabolism improving agent of the present invention is not specifically limited, but oral administration is preferred.

In the case of oral administration, the complex of the present invention may be administered as it is, or in the form of compositions prepared by conventional methods using excipients which are acceptable as ingredients of food or

5 drugs.

As the excipients, saccharides such as sorbitol, lactose and glucose, inorganic substances such as dextrin, starch, calcium carbonate and calcium sulfate, crystalline cellulose, distilled water, sesame oil, corn oil, olive  
10 oil, cottonseed oil, and other generally employed excipients can be used.

In preparing the compositions, additives such as binders, lubricants, dispersing agents, suspending agents, emulsifiers, diluents, buffers, antioxidants, and  
15 antibacterial agents may be used.

The dose of the composition will vary depending on various factors such as the patient's age, sex and physical condition, administration route, administration schedule, and form of composition. For instance, when the  
20 composition is orally administered to an adult, it is suitable to administer the composition in an amount of 2-100 g/day in 1 to 4 parts. Administration may be made at a dose outside the above limit as may be required.

The lipid metabolism improving agent of the present invention can be used not only as a cholesterol metabolism improving agent but also as an agent for the treatment or prevention of diseases such as fatty liver, hypertension, hyperlipidemia, arteriosclerosis, obesity, diabetes, and myocardial infarction.

The functional food of the present invention can be produced by adding the protein hydrolyzate/phospholipid complex containing 10% or more of bound phospholipid to food materials in a conventional process for producing food. The functional food contains 0.1% or more,  
35 preferably 0.1-50%, more preferably 0.5-30% of the complex. The functional food may additionally be formulated to

contain a protein, a sugar, a fat, a trace element, a vitamin, an emulsifier, a flavor, and the like.

- The term functional food as used herein refers to food designed and processed so that food ingredients may fully perform their functions for the biophylaxis, regulation of biorhythm, and regulation of physical condition relating to the prevention of and recovery from diseases.

- Examples of the food are juice, soft drinks, tea, lactic acid beverages, ices, milk, dairy products (e.g. butter, cheese, yogurt, processed milk, and skim milk), meat, meat products (e.g. ham, sausage, and hamburger), fish, fish products (e.g. steamed, baked or fried fish paste), egg, egg products (e.g. fried or steamed foods made of beaten eggs), confectionery (e.g. cookies, jelly, and snacks), bread, noodles, pickles, smoked fish and meat, dried fish, preserved foods boiled down with soy, salted foods, soup, and seasonings.

- The functional food of the present invention may be in the form of ordinary food, or in the form of liquid food, pre-digested nutrient food, elemental diet, liquid nutrient food, or the like.

- The functional food of the present invention can be used not only for improving lipid metabolism, particularly cholesterol metabolism, but also for treating, preventing or alleviating diseases such as fatty liver, hypertension, hyperlipidemia, arteriosclerosis, obesity, diabetes, and myocardial infarction. It is suitable to give the functional food to an adult in an amount of 2-100 g/day.

- The effect of the complexes of the present invention is shown below by Test Examples.

#### Test Example 1

##### Test Method

- Five-weeks-old male Wistar rats were used as test animals. The rats were fed with a commercially available solid feed (MF, Oriental Yeast Co., Ltd.) for three days,

and then divided into groups each consisting of 6 animals in such a way that there is no significant difference in body weight of the animals between the groups. The test feed compositions were formulated, as shown in Table 1, to respectively contain a protein at a protein level of 20% and to contain sucrose in amounts adjusted so as to make the total weights of all the compositions equal. After groups of test animals were fed with equal amounts of the respective feed compositions for 10 days, the total cholesterol concentration in serum, the high density lipoprotein (HDL) cholesterol concentration in serum, and the total cholesterol concentration in liver were measured for each rat.

15 Table 1

Ingredient	Test Group			
	1	2	3	4
	(%)	(%)	(%)	(%)
Protein*1	23.05	28.65	28.45	30.05
(Protein level)	(20)	(20)	(20)	(20)
Methionine*2	0.1	0.1	0.1	0.1
Lard	5	5	5	5
Corn oil	1	1	1	1
Mineral mixture*3	3.5	3.5	3.5	3.5
(AIN-76)				
Vitamin mixture	1	1	1	1
(AIN-76)				
Choline chloride	0.2	0.2	0.2	0.2
Cellulose	5	5	5	5
Sucrose	60.4	54.8	55.0	53.4
Cholesterol	0.5	0.5	0.5	0.5
Sodium cholate	0.25	0.25	0.25	0.25

Notes)

\*1 (Protein)

- Group 1: Promic P (isolated soybean protein) (bound phospholipid content: 1%)
- 5 Group 2: Mixture of Promic P and SLP-White (soybean lecithin) obtained in Comparative Example 1 (bound phospholipid content: 0.8%, free phospholipid content: 20%)
- 10 Group 3: Protein/phospholipid complex obtained in Example 3 (Promic P/SLP-White complex) (bound phospholipid content: 20%, free phospholipid content: 1.0%)
- 15 Group 4: Protein/enzyme-modified phospholipid complex obtained in Example 2 (Promic P/Elmizer AC complex) (bound phospholipid content: 20%, free phospholipid content: 1.0%)
- \*2: Methionine, an essential amino acid, was added in order to make the nutritive values of all the compositions equal.
- 20 \*3: American Institute of Nutrition [*J. of Nutrition*, 107, 1340 (1977)]

The results are shown in Table 2.

25

Table 2

Test Group	Total Cholesterol Conc. in Serum (mg/dl)	HDL Cholesterol Conc. in Serum (mg/dl)	Arterio-sclerosis Index*	Total Cholesterol Conc. in Liver (mg/g of liver)
1	111.0±10.0	14.3±1.0	0.14±0.01	25.1±1.3
2	80.8± 6.4	20.0±0.9	0.25±0.02	22.3±1.0
3	79.3± 7.1	25.5±1.7	0.33±0.02	19.2±1.2
4	77.2± 4.5	26.2±1.0	0.35±0.02	16.3±1.3

(Numerical value: mean ± standard error)

Note)\* The arteriosclerosis index shows the value of (HDL cholesterol conc. in serum)/(total cholesterol conc. in serum).

As shown in the above table, Test Groups 3 and 4 were almost equal to Test Group 2 in total cholesterol concentration in serum, but showed higher HDL cholesterol concentration in serum as compared with Test Groups 1 and 2. The relationship between the total cholesterol concentration in serum and the HDL cholesterol concentration in serum was expressed as the arteriosclerosis index. Test Groups 3 and 4 showed higher arteriosclerosis index as compared with Test Groups 1 and 2, which indicates that the cholesterol metabolism in serum was improved in Test Groups 3 and 4. Test groups 3 and 4 also showed lower total cholesterol concentration in liver as compared with Test Groups 1 and 2. No significant difference was observed in feed intake or increase in body weight between the test groups.

#### Test Example 2

The test was carried out in the same manner as in Test Example 1, except that the feed compositions shown in Table 3 were used. The results are shown in Table 4.

Table 3

Ingredient	Test Group	
	5	6
	(%)	(%)
Protein*1	34.35	32.65
(Protein)	(20)	(20)
Lard	5	5
Corn oil	1	1
Mineral mixture	3.5	3.5
(AIN-76)		
Vitamin mixture	1	1
(AIN-76)		
Choline chloride	0.2	0.2
Cellulose	5	5
Sucrose	49.2	50.9
Cholesterol	0.5	0.5
Sodium cholate	0.25	0.25

Note)

\*1 (Protein)

- 5 Group 5: Mixture of Promic P hydrolyzate and SLP-White obtained in Comparative Example 3 (bound phospholipid content: 0.8%, free phospholipid content: 20%)

- 10 Group 6: Protein hydrolyzate/phospholipid complex obtained in Example 9 (Promic P hydrolyzate/SLP-White complex) (bound phospholipid content: 20%, free phospholipid content: 1.0%)

Table 4

Test Group	Total Cholesterol Conc. in Serum (mg/dl)	HDL Cholesterol Conc. in Serum (mg/dl)	Arterio-sclerosis Index	Total Cholesterol Conc. in Liver (mg/g of liver)
5	72.7±3.1	35.2±1.3	0.49±0.03	7.4±0.7
6	68.3±3.6	32.0±2.3	0.49±0.03	4.7±0.4

15

(Numerical value: mean ± standard error)

As shown in the above table, Test Group 6 was equal to Test Group 5 in arteriosclerosis index, but showed lower total cholesterol concentration in liver. No significant difference was observed in feed intake or increase in body weight between the test groups.

### Test Example 3

The test was carried out in the same manner as in Test Example 1, except that the feed compositions shown in Table 5 were used. The results are shown in Table 6.

Table 5

Ingredient	Test Group		
	7	8	9
	(%)	(%)	(%)
Protein*1	23.05	32.3	34.8
(Protein level)	(20)	(20)	(20)
Methionine	0.1	0.04	0.04
Tryptophan	0	0.01	0.01
Lard	5	5	5
Corn oil	1	1	1
Mineral mixture	3.5	3.5	3.5
(AIN-76)			
Vitamin mixture	1	1	1
(AIN-76)			
Choline chloride	0.2	0.2	0.2
Cellulose	5	5	5
Sucrose	60.4	51.2	48.7
Cholesterol	0.5	0.5	0.5
Sodium cholate	0.25	0.25	0.25

Note)

\*1 (Protein)

Group 7: Promic P (bound phospholipid content: 1%)

Group 8: Hydrolyzate of soybean protein/enzyme-modified lecithin complex (Promic P/Elmizer AC complex)



obtained in Example 5 (bound phospholipid content: 20%, free phospholipid content: 0.5%)

Group 9: Soybean protein hydrolyzate/enzyme-modified lecithin complex obtained in Example 8 (Promic P hydrolyzate/Elmizer AC complex) (bound phospholipid content: 20%, free phospholipid content: 1.0%)

Table 6

Test Group	Total Cholesterol Conc. in Serum (mg/dl)	HDL Cholesterol Conc. in Serum (mg/dl)	Arterio-sclerosis Index	Total Cholesterol Conc. in Liver (mg/g of liver)
7	103.8±9.7	34.7±2.5	0.35±0.04	28.7±1.5
8	75.4±5.3	53.4±3.1	0.71±0.02	4.3±0.3
9	81.4±4.7	53.5±2.7	0.73±0.02	5.3±0.3

(Numerical value: mean ± standard error)

As shown in the above table, the arteriosclerosis indices of Test Groups 8 and 9 were higher than that of Test Group 7, which indicates that the cholesterol metabolism in serum was improved in Test Groups 8 and 9. In addition, Test Groups 8 and 9 showed total cholesterol concentration in liver much lower than that of Test Group 7; the total cholesterol concentration in liver of Test Group 8 was lower than that of Test Group 9. No significant difference was observed in feed intake or increase in body weight between the test groups.

#### Test Example 4

The test was carried out in the same manner as in Test Example 1, except that the feed compositions shown in Table 7 were used. The results are shown in Table 8.

Table 7

Ingredient	Test Group				
	10	11	12	13	14
	(%)	(%)	(%)	(%)	(%)
Protein*1	27.59	28.69	28.69	37.15	40.65
(Protein level)	(20)	(20)	(20)	(20)	(20)
Tryptophan	0.04	0.04	0.04	0.02	0.02
Lysine	0.82	0.82	0.82	0.72	0.72
Threonine	0.2	0.2	0.2	0.16	0.16
Lard	5	5	5	5	5
Corn oil	1	1	1	1	1
Mineral mixture*3	3.5	3.5	3.5	3.5	3.5
(AIN-76)					
Vitamin mixture	1	1	1	1	1
(AIN-76)					
Choline chloride	0.2	0.2	0.2	0.2	0.2
Cellulose	5	5	5	5	5
Sucrose	54.9	53.8	53.8	45.5	42.0
Cholesterol	0.5	0.5	0.5	0.5	0.5
Sodium cholate	0.25	0.25	0.25	0.25	0.25

Note)

\*1 (Protein)

5 Group 10: Wheat gluten (bound phospholipid content: 0.3%)

Group 11: Mixture of wheat gluten and enzyme-modified lecithin obtained in Comparative Example 2 (bound phospholipid content: 0.3%, free phospholipid content: 10%)

10 Group 12: Wheat gluten/enzyme-modified lecithin complex obtained in Example 1 (bound phospholipid content: 10%, free phospholipid content: 1.0%)

15 Group 13: Hydrolyzate of wheat gluten/enzyme-modified lecithin complex obtained in Example 4 (bound

phospholipid content: 10%, free phospholipid content: 0.3%)

Group 14: Wheat gluten hydrolyzate/enzyme-modified lecithin complex obtained in Example 7 (bound phospholipid content: 10%, free phospholipid content: 1.0%)

Table 8

Test Group	Total Cholesterol Conc. in Serum (mg/dl)	HDL Cholesterol Conc. in Serum (mg/dl)	Arterio-sclerosis Index	Total Cholesterol Conc. in Liver (mg/g of liver)
10	132.5± 7.4	16.7±1.4	0.13±0.02	22.8±1.0
11	113.7±10.3	15.8±1.2	0.14±0.01	26.5±2.5
12	83.5± 6.9	21.5±1.8	0.27±0.03	19.9±1.3
13	62.2± 5.6	34.8±1.8	0.58±0.04	7.3±0.4
14	79.6± 6.7	28.7±2.4	0.37±0.03	18.9±1.5

(Numerical value: mean ± standard error)

As shown in the above table, the arteriosclerosis indices of Test Groups 12-14 were higher than those of Test Groups 10 and 11, which indicates that the cholesterol metabolism in serum was improved in Test Groups 12-14. In addition, Test Groups 12-14 showed lower total cholesterol concentration in liver as compared with Test Groups 10 and 11; in particular, the total cholesterol concentration in liver of Test Group 13 was much the lowest. No significant difference was observed in feed intake or increase in body weight between the test groups.

Certain embodiments of the invention are illustrated in the following Examples and Comparative Examples.

## 25 Best Mode for Carrying Out the Invention

### Example 1

To 1 kg of Regular Gluten A (wheat gluten, Bunge, bound phospholipid content: 0.3%) was added 2.4 l of a 5%

1 solution prepared by dispersing Elmizer AC (enzyme-modified lecithin, Kyowa Hakko Kogyo Co., Ltd.) in water. The mixture was kneaded by using a baker's mixer (100 r.p.m.) at room temperature for 10 minutes. The resulting reaction  
 5 mixture was freeze-dried and then pulverized to obtain about 1.1 kg of a protein/phospholipid complex (bound phospholipid content: 10%, free phospholipid content: 1.0%).

#### 10 Example 2

To 1 kg of Promic P (isolated soybean protein, Kyowa Hakko Kogyo Co., Ltd., bound phospholipid content: 1.0%) was added 10 L of a 2.5% solution prepared by dispersing Elmizer AC in water. The mixture was stirred rapidly  
 15 (10,000 r.p.m.) at room temperature for 10 minutes. The resulting reaction mixture was freeze-dried and then pulverized to obtain 1.1 kg of a protein/phospholipid complex (bound phospholipid content: 20%, free phospholipid content: 1.0%).

20

#### Example 3

The same procedure as in Example 2 was repeated, except that SLP-White (purified soybean lecithin, True Lecithin mfg. Co., Ltd.) was used in place of Elmizer AC,  
 25 whereby about 1.1 kg of a protein/phospholipid complex (bound phospholipid content: 20%, free phospholipid content: 1.0%) was obtained.

#### Example 4

30 The protein/phospholipid complex obtained in Example 1 (1 kg) was dispersed in 9 L of water, followed by addition of 2 N hydrochloric acid to adjust the solution to pH 2. To the resulting solution was added pepsin [activity; 1:10,000 (this means that 1 g of the pepsin is capable of  
 35 hydrolyzing 10,000 g of egg white protein at 50°C in 2 hours under acidic conditions with hydrochloric acid),

- Nacalai Tesque, Inc.) in an amount of 1% based on the protein/phospholipid complex. The mixture was allowed to stand at 37°C for 24 hours, followed by heating at 90°C for one hour to stop the reaction. The reaction mixture was
- 5 neutralized with 2 N sodium hydroxide, and then centrifuged. To the obtained precipitate was added water, and the mixture was centrifuged again. This procedure was repeated twice, whereby the precipitate was washed. The precipitate was freeze-dried and then pulverized to obtain
  - 10 200 g of a hydrolyzate of the protein/phospholipid complex which is slightly soluble in water (molecular weight: ca. 15,000, bound phospholipid content: 10%, free phospholipid content: 0.3%). The molecular weight was determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel
  - 15 electrophoresis (the same method was employed for the determination of molecular weight in the following Examples).

#### Example 5

- 20 The same procedure as in Example 4 was repeated, except that the protein/phospholipid complex obtained in Example 2 was used in place of the protein/phospholipid complex obtained in Example 1, whereby 200 g of a hydrolyzate of the protein/phospholipid complex which is
- 25 slightly soluble in water (molecular weight: ca. 15,000, bound phospholipid content: 20%, free phospholipid content: 0.5%) was obtained.

- The nitrogen contents of the protein used as the starting material and the protein contained in the obtained
- 30 hydrolyzate of the protein/phospholipid complex were respectively determined by the Kjeldahl method. Multiplication of the obtained values by a conversion factor of 6.25 gave the weights of the proteins, and the protein recovery calculated as the ratio of the amount of
  - 35 the protein contained in the hydrolyzate to that of the protein used as the starting material was 19.1%.

Example 6

The same procedure as in Example 4 was repeated, except that the protein/phospholipid complex obtained in Example 3 was used in place of the protein/phospholipid complex obtained in Example 1, whereby 200 g of a hydrolyzate of the protein/phospholipid complex which is slightly soluble in water (molecular weight: ca. 15,000, bound phospholipid content: 20%, free phospholipid content: 0.5%) was obtained.

Example 7

Regular Gluten A (bound phospholipid content: 0.3%) (1 kg) was dispersed in 9 l of water, followed by addition of 2 N hydrochloric acid to adjust the solution to pH 2. To the resulting solution was added pepsin (activity; 1:10,000, Nacalai Tesque, Inc.) in an amount of 1% based on Regular Gluten A. The mixture was allowed to stand at 37°C for 24 hours, followed by heating at 90°C for one hour to stop the reaction. The reaction mixture was neutralized with 2 N sodium hydroxide, and then centrifuged. To the obtained precipitate was added water, and the mixture was centrifuged again. This procedure was repeated twice, whereby the precipitate was washed. The precipitate was freeze-dried and then pulverized to obtain 200 g of a protein hydrolyzate (molecular weight: ca. 15,000). To 200 g of the obtained protein hydrolyzate was added 1.0 l of a 2.5% solution prepared by dispersing Elmizer AC in water, and the mixture was stirred rapidly (10,000 r.p.m.). The resulting reaction mixture was freeze-dried and then pulverized to obtain 220 g of a protein hydrolyzate/phospholipid complex (bound phospholipid content: 10%, free phospholipid content: 1.0%).

Example 8

Promic P (bound phospholipid content: 1.0%) (1 kg) was dispersed in 9 l of water, followed by addition of 2 N

hydrochloric acid to adjust the solution to pH 2. To the resulting solution was added pepsin (activity; 1:10,000, Nacalai Tesque, Inc.) in an amount of 1% based on Promic P. The mixture was allowed to stand at 37°C for 24 hours, followed by heating at 90°C for one hour to stop the reaction. The reaction mixture was neutralized with 2 N sodium hydroxide, and then centrifuged. To the obtained precipitate was added water, and the mixture was centrifuged again. This procedure was repeated twice, whereby the precipitate was washed. The precipitate was freeze-dried and then pulverized to obtain 200 g of a protein hydrolyzate (molecular weight: ca. 15,000). To 200 g of the obtained protein hydrolyzate was added 2.0 l of a 2.5% solution prepared by dispersing Elmizer AC in water, and the mixture was stirred rapidly (10,000 r.p.m.). The resulting reaction mixture was freeze-dried and then pulverized to obtain 250 g of a protein hydrolyzate/phospholipid complex (bound phospholipid content: 20%, free phospholipid content: 1.0%).

The protein recovery calculated as the ratio of the amount of the protein contained in the obtained protein hydrolyzate/phospholipid complex to that of the protein used as the starting material in the same manner as in Example 5 was 12.4%.

#### Example 9

The same procedure as in Example 8 was repeated, except that SLP-White was used in place of Elmizer AC, whereby 250 g of a protein hydrolyzate/phospholipid complex (bound phospholipid content: 20%, free phospholipid content: 1.0%) was obtained.

#### Comparative Example 1

Promic P (bound phospholipid content: 1.0%) (1 kg) was mixed with 250 g of SLP-White to obtain 1250 g of a

protein/phospholipid mixture (bound phospholipid content: 0.8%, free phospholipid content: 20%).

#### Comparative Example 2

- 5 Regular Gluten A (bound phospholipid content: 0.3%) (1 kg) was mixed with 110 g of Elmizer AC to obtain 1110 g of a protein/enzyme-modified lecithin mixture (bound phospholipid content: 0.3%, free phospholipid content: 10%).

10

#### Comparative Example 3

- Promic P (bound phospholipid content: 1%) (1 kg) was dispersed in 9 l of water, followed by addition of 2 N hydrochloric acid to adjust the solution to pH 2. To the resulting solution was added pepsin (activity; 1:10,000, Nacalai Tesque, Inc.) in an amount of 1% based on Promic P. The mixture was allowed to stand at 37°C for 24 hours, followed by heating at 90°C for one hour to stop the reaction. The reaction mixture was neutralized with 2 N sodium hydroxide, and then centrifuged. To the obtained precipitate was added water, and the mixture was centrifuged again. This procedure was repeated twice, whereby the precipitate was washed. The precipitate was freeze-dried and then pulverized to obtain 200 g of a protein hydrolyzate (molecular weight: ca. 15,000). The obtained protein hydrolyzate (1 kg) was mixed with 250 g of SLP-White to obtain 1250 g of a protein hydrolyzate/phospholipid mixture (bound phospholipid content: 0.8%, free phospholipid content: 20%).

30

#### Example 10

Hamburgers (two servings) are prepared from the following ingredients.

- |    |             |       |
|----|-------------|-------|
| 35 | Onion       | Half  |
|    | Minced meat | 100 g |



	Water	29.2 g
	Lard	11.8 g
5	Slightly water-soluble product obtained in Example 5	9 g
	Egg	One
	Crumbs	Small quantity
10	Seasonings	Small quantity

Example 11

Cookies (30 pieces) are prepared from the following ingredients.

15	Soft flour	100 g
	Starch	74 g
	Water	14 g
20	Slightly water-soluble product obtained in Example 5	9 g
	Baking powder	2 Tsp.
	Salt	1/2 Tsp.
	Egg	One
25	Butter	80 g
	Milk	2 Tbsp.
	Honey	Small quantity

Example 12

30 A powdery protein to be used in a liquid preparation is prepared from the following ingredients.

	Slightly water-soluble product obtained in Example 5	80 g
35	Casein sodium	17.5 g
	L-Valine	0.5 g
	Ferric pyrophosphate (iron source)	0.1 g
40	Phoscal EFC (calcium source, Nikko Fine Products)	1 g

Vitamin Mix (Merck & Co., Inc.) 1 g

A liquid preparation is prepared by dispersing 20 g of the powdery protein in 180 ml of water.

5

### Example 13

Tablets are prepared from the following ingredients.

10	Slightly water-soluble product obtained in Example 5	2 g
	Powdery sugar	2.6 g
	Ascorbic acid	150 mg
	Citric acid	0.1 g
	Sucrose stearate	150 mg
15	Flavor	15 mg

### Industrial Applicability

The present invention provides a lipid metabolism  
20 improving agent and a functional food.

## CLAIMS

1. A protein/phospholipid or protein hydrolyzate/  
phospholipid complex containing 10 wt% or more of bound  
5 phospholipid.
2. The complex according to claim 1 which is  
prepared by mixing a protein hydrolyzate with a  
phospholipid.
- 10 3. The complex according to claim 1 which is  
prepared by mixing a protein with a phospholipid to form a  
complex and hydrolyzing the protein moiety of the formed  
complex.
- 15 4. The complex according to claim 1 which contains  
10-50 wt% of bound phospholipid.
5. The complex according to claim 1 which contains  
20 20-50 wt% of bound phospholipid.
6. The complex according to claim 1 wherein the  
protein is derived from wheat, soybean, corn, or milk.
- 25 7. The complex according to claim 1 wherein the  
phospholipid is lecithin.
8. The complex according to claim 1 wherein the  
phospholipid is enzyme-modified lecithin.
- 30 9. A lipid metabolism improving agent comprising a  
protein/phospholipid or protein hydrolyzate/phospholipid  
complex containing 10 wt% or more of bound phospholipid.
- 35 10. The lipid metabolism improving agent according to  
claim 9 in an effective amount which is in pharmaceutically

acceptable dosage form comprising a pharmaceutically acceptable carrier.

11. A cholesterol metabolism improving agent  
5 comprising a protein/phospholipid or protein hydrolyzate/  
phospholipid complex containing 10 wt% or more of bound  
phospholipid.

12. The cholesterol metabolism improving agent  
10 according to claim 11 in an effective amount which is in  
pharmaceutically acceptable dosage form comprising a  
pharmaceutically acceptable carrier.

13. A functional food comprising a protein/  
15 phospholipid or protein hydrolyzate/phospholipid complex  
containing 10 wt% or more of bound phospholipid.

14. The functional food according to claim 13 which  
contains 0.1 wt% or more of the complex.  
20

15. The functional food according to claim 13 or 14  
having lipid metabolism improving activity.

16. The functional food according to claim 13 or 14  
25 having cholesterol metabolism improving activity.

17. A method for improving the lipid metabolism of an  
animal which comprises administering to the animal the  
complex according to claim 1.  
30

18. A method for improving the cholesterol metabolism  
of an animal which comprises administering to the animal  
the complex according to claim 1.

19. The use of the complex according to claim 1 for  
35 improving the lipid metabolism of an animal.

20. The use of the complex according to claim 1 for improving the cholesterol metabolism of an animal.

21. The use of the complex according to claim 1 for the preparation of pharmaceutical compositions useful for improving the lipid metabolism of an animal.

22. The use of the complex according to claim 1 for the preparation of pharmaceutical compositions useful for improving the cholesterol metabolism of an animal.

23. The use of the complex according to claim 1 for the preparation of functional foods useful for improving the lipid metabolism of an animal.

24. The use of the complex according to claim 1 for the preparation of functional foods useful for improving the cholesterol metabolism of an animal.

25. A process for preparing a protein hydrolyzate/phospholipid complex which comprises mixing a protein hydrolyzate with a phospholipid and recovering the formed complex.

26. A process for preparing a protein hydrolyzate/phospholipid complex which comprises mixing a protein with a phospholipid to form a complex; hydrolyzing the protein moiety of the complex in an aqueous medium; and recovering the formed protein hydrolyzate/phospholipid complex.

27. The process according to claim 26 wherein the hydrolysis of the protein moiety is carried out by the treatment with an enzyme source having proteolytic activity.

## ABSTRACT

The present invention relates to a protein/  
 phospholipid or protein hydrolyzate/phospholipid complex  
 5 containing 10 wt% or more of bound phospholipid, a lipid  
 metabolism improving agent comprising the complex, and a  
 functional food comprising the complex.

The present invention provides a lipid metabolism  
 improving agent and a functional food, containing the  
 10 complex.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
221

# DECLARATION AND POWER OF ATTORNEY FILED WITH U.S. DESIGNATED OFFICE UNDER 35 U.S.C. 371(c)(4)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

LIPID METABOLISM IMPROVING AGENT

the specification of which was filed as PCT International Application No. PCT/JP96/02549

filed September 6, 1996 and was amended on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

## Prior Foreign Application(s)

## Priority Claimed

<u>228928/95</u>	<u>JAPAN</u>	<u>06/09/95</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u>                    </u>	<u>                    </u>	<u>                    </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u>                    </u>	<u>                    </u>	<u>                    </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u>                    </u>	<u>                    </u>	<u>                    </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u>                    </u>	<u>                    </u>	<u>                    </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u>                    </u>	<u>                    </u>	<u>                    </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112.1, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>                    </u>	<u>                    </u>	<u>                    </u>
(Application Serial No.)	(Filing Date)	(Status: patented, pending, abandoned)
<u>                    </u>	<u>                    </u>	<u>                    </u>
(Application Serial No.)	(Filing Date)	(Status: patented, pending, abandoned)
<u>                    </u>	<u>                    </u>	<u>                    </u>
(Application Serial No.)	(Filing Date)	(Status: patented, pending, abandoned)
<u>                    </u>	<u>                    </u>	<u>                    </u>
(Application Serial No.)	(Filing Date)	(Status: patented, pending, abandoned)

I hereby appoint as principal attorneys: Donald R. Antonelli, Reg. No. 20,296; David T. Terry, Reg. No. 20,178; Melvin Kraus, Reg. No. 22,466; Stanley A. Wal, Reg. No. 26,432; William I. Solomon, Reg. No. 28,565; Gregory E. Montone, Reg. No. 28,141; Ronald J. Shore, Reg. No. 28577; Donald E. Stout, Reg. No. 26,422; Alan E. Schiapelli, Reg. No. 32,087; James N. Dresser, Reg. No. 22,973 and Carl I. Brundidge, Reg. No. 29,621 to prosecute and transact all business connected with this application and any related United States application and international applications. Please direct all communications to the following address:

Antonelli, Terry, Stout & Kraus  
Suite 1800  
1300 North Seventeenth Street  
Arlington, Virginia 22209  
Telephone: (703)312-6600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date April 10, 1997 Inventor Goro Hori  
Inventor's Signature Goro Hori  
Residence Same as Post Office Address Citizenship Japan  
Post Office Address 2-403-1-401, Arakawaoki-Nishi-ku, Tsuchiura-shi,  
Ibaraki 300-11 Japan

Date April 8, 1997 Inventor Kazuhiro Matsuoka  
Inventor's Signature Kazuhiro Matsuoka  
Residence Same as Post Office Address Citizenship Japan  
Post Office Address 1-18-20, Motoizumi, Komae-shi, Tokyo 201 Japan

Date April 10, 1997 Inventor Iwao Sato  
Inventor's Signature Iwao Sato  
Residence Same as Post Office Address Citizenship Japan  
Post Office Address 17-22-204, Bunkyo-cho, Tsuchiura-shi,  
Ibaraki 300 Japan

Date April 4, 1997 Inventor Satoshi Nagasaka  
Inventor's Signature Satoshi Nagasaka  
Residence Same as Post Office Address Citizenship Japan  
Post Office Address 2-55-1, Yajima-cho, Gifu-shi, Gifu 500 Japan